For risk of CNS toxicity, the DEBBRAH phase II study showed that intracranial activity of T-Dxd and radiation is feasible with manageable toxicity in patients with HER2-positive and HER2-low breast cancer who received mainly WBRT and/or stereotactic radiosurgery (SRS). The gene discussed is ERBB2; the disease is breast carcinoma.